Methods for treating pruritus 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
CA2892393 A1 2014-06-19 [CA2892393] / 2014-06-19
申请号/申请日
2013CA-2892393 / 2013-12-13
发明人
SCIASCIA THOMAS;
申请人
TREVI THERAPEUTICS;
主分类号
IPC分类号
A01N-043/42A61K-031/485A61P-025/00
摘要
(CA2892393) The present invention relates to methods for treating pruritus with anti-pruritic compositions.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2012US-13715625 2012-12-14 2012US-61737488 2012-12-14 2013WO-US75096 2013-12-13
主权利要求
(CA2892393)  What is claimed is: 1. A method of treating pruritus comprising administering an effective amount of an anti-pruritus agent to a subject in need of such treatment, wherein the antipruritus agent is nalbuphine or a pharmaceutically acceptable salt or ester thereof 2. The method of claim 1, wherein said subject is suffering from a pruritic condition, and said pruritic condition comprises atopic dermatitis, nervous dermatitis, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, caterpillar dermatitis, asteatosis, senile pruritus cutaneous, insect sting, photosensitive dermatosis, urticaria, prurigo, herpes, impetigo, eczema, tinea, lichen, psoriasis, scabies and acne vulgaris, or visceral diseases complicated with pruritus. 3. The method of claim 2, wherein said visceral diseases complicated with pruritus comprise malignant tumors, diabetes mellitus, hepatic diseases, renal failure or pregnancy. 4. The method of claim 1, wherein said subject is suffering from a skin change comprising pruritus secondary to inflamed skin, pruritus arising from conditions of non-diseased skin, pruritus associated with chronic secondary scratch, or skin lesions resulting from an underlying medical condition. 5. The method of claim 4, wherein said underlying medical condition has an origin comprising dermatologic origin, systemic disease origin, neurologic origin, psychogenic origin, or mixed origin. 6. The method of claim 1, wherein said subject has uremic pruritus or prurigo nodularis. 7. The method of claim 1, wherein the anti-pruritus agent is administered at an initial oral dose of from about 15 mg to about 30 mg twice a day and then titrated to an effective dose. 8. The method of claim 1, wherein the anti-pruritus agent is administered at an initial dose of from about 15 mg to about 30 mg once a day and then titrated to an effective dose. 9. The method of claim 1, wherein the anti-pruritus agent is administered at an initial dose of from about 15 mg to about 30 mg twice a day or once a day for about 2- 3 days and then titrated to an effective dose at about 15 mg to about 30 mg increment. 10. The method of claim 1, wherein the maximum dose of the anti-pruritus agent is about 480 mg when said agent is administered to a subject twice a day or about 240 mg when said agent is administered to a subject once a day. 11. The method of claim 1, wherein the anti-pruritus agent is administered with an AM dosage and a PM dosage and wherein the PM dosage is higher than the AM dosage, or vice versa. 12. The method of claim 1, wherein the anti-pruritus agent is administered at a dose of about 60 mg or about 120 mg twice a day to a subject with uremic pruritus or renal impairment or about 90 mg or about 180 mg twice a day to a subject without a renal impairment condition. 13. The method of claim 1, wherein the anti-pruritus agent is in an extended release oral dosage form and the administration provides in the subject a mean C max of from about 1 ng/mL to about 90 ng/mL, from about 5 ng/mL to about 85 ng/mL, from about 5 ng/ml to about 45 ng/ml, from about 25 ng/mL to about 72 ng/mL, or from about ng/mL to about 28 ng/mL. 14. The method of claim 1, wherein the anti-pruritus agent is in an extended release oral dosage form and the administration provides in the subject an AUC(0-.infin.) of from about 40 ng - hr/mL to about 3000 ng - hr/mL, 40 ng - hr/mL to about 800 ng - hr/mL or 30 ng - hr/mL to about 360 ng - hr/mL. 15. The method of claim 1, wherein one or more of the metabolites of the antipruritus agent do not have detectable anti-pruritus activity. 16. The method of claim 1, wherein the anti-pruritus agent is not administered in combination with a second anti-pruritus agent. 17. The method of claim 1, wherein the anti-pruritus agent is in an extended release oral dosage form. 18. The method of claim 17, wherein the administration provides in the subject a pK release profile with the characteristics of a) a mean C max from about 1.5 ng/mL to about 195 ng/mL, and b) AUC(0-.infin.) from about 20 ng - hr/mL to about 4100 ng - hr/mL. 19. The method of claim 17, wherein the administration provides in the subject a pK release profile with the characteristics of a) a mean C max from about 1.5 ng/mL to about 60 ng/mL, and b) AUC(0-.infin.) from about 20 ng - hr/mL to about 700 ng - hr/mL. 20. The method of claim 17, wherein the anti-pruritus agent is administered in a formulation comprising nalbuphine hydrochloride, mannitol, hydroxypropyl cellulose, locust bean gum, xanthan gum, calcium sulfate dihydrate and magnesium stearate.
法律状态
(CA2892393) LEGAL DETAILS FOR CA2892393  Actual or expected expiration date=2033-12-13    Legal state=ALIVE    Status=PENDING     Event publication date=2013-12-13  Event code=CA/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=CA CA2892393  Application date=2013-12-13  Standardized application number=2013CA-2892393     Event publication date=2014-06-19  Event code=CA/A1  Event type=Examination events  Application laid open  Publication country=CA  Publication number=CA2892393  Publication stage Code=A1  Publication date=2014-06-19  Standardized publication number=CA2892393
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部